Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years

The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.

Previous post The 2024 box office is a franchise frenzy — at a time when audiences are feeling IP fatigue
Next post Cruise stocks pull back after record 2023 gains, led by Norwegian, Royal Caribbean share selloffs